Literature DB >> 3179437

Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant.

J B Porter1, M Gyparaki, L C Burke, E R Huehns, P Sarpong, V Saez, R C Hider.   

Abstract

A series of bidentate hydroxypyridinone iron chelators that have therapeutic potential as oral iron chelators, have been studied systematically to determine which properties are the most critical for the mobilization of hepatocyte iron. The relationship between lipid solubility of the free and complexed forms of each chelator and hepatocyte iron release has been investigated as well as the contribution of the binding constant for iron (III). Hydroxypyridin-4-ones that were approximately equally soluble in lipid and aqueous phases were the most active compounds, the partition coefficient of the free chelator appearing to be more critical in determining iron release than that of the iron-complexed form. Highly hydrophilic chelators did not mobilize intracellular iron pools, whereas highly lipophilic compounds were toxic to hepatocytes. The contribution of the binding constant for iron (III) to cellular iron release was assessed by comparing hydroxypyridin-4-ones (log beta 3 = 36) and hydroxypyridin-2-ones (log beta 3 = 32), which possess similar partition coefficients. The results show that the binding for iron (III) is particularly important at low concentrations of chelator (less than 100 mumol/L) and that at higher concentrations (greater than 500 mumol/L) iron mobilization is limited by the available chelatable pool. Measurement of iron release with other chelators confirms the importance of both the lipid solubilities and iron (III)-binding constants to iron mobilization. The most active hydroxypyridin-4-ones released more hepatocyte iron than did deferoxamine when compared at equimolar concentrations. The results suggest that the ability of an iron chelator to enter the cell is crucial for effective iron mobilization and that once within the cell the binding constant of the chelator for iron (III) becomes a dominant factor.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3179437

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

1.  Selective determination of mitochondrial chelatable iron in viable cells with a new fluorescent sensor.

Authors:  Frank Petrat; Daniela Weisheit; Martina Lensen; Herbert de Groot; Reiner Sustmann; Ursula Rauen
Journal:  Biochem J       Date:  2002-02-15       Impact factor: 3.857

2.  Subcellular distribution of chelatable iron: a laser scanning microscopic study in isolated hepatocytes and liver endothelial cells.

Authors:  F Petrat; H de Groot; U Rauen
Journal:  Biochem J       Date:  2001-05-15       Impact factor: 3.857

3.  Design, Synthesis, and Testing of Polyamine Vectored Iron Chelators.

Authors:  Raymond J Bergeron; Shailendra Singh; Neelam Bharti; Yi Jiang
Journal:  Synthesis (Stuttg)       Date:  2010       Impact factor: 3.157

4.  Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  Methods Mol Biol       Date:  2010

Review 5.  Role of metal dyshomeostasis in Alzheimer's disease.

Authors:  David J Bonda; Hyoung-gon Lee; Jeffrey A Blair; Xiongwei Zhu; George Perry; Mark A Smith
Journal:  Metallomics       Date:  2011-02-07       Impact factor: 4.526

6.  Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.

Authors:  Erika M Becker; David B Lovejoy; Judith M Greer; Ralph Watts; Des R Richardson
Journal:  Br J Pharmacol       Date:  2003-03       Impact factor: 8.739

7.  Role of iron and glutathione redox cycle in acetaminophen-induced cytotoxicity to cultured rat hepatocytes.

Authors:  Y Ito; Y Suzuki; H Ogonuki; H Hiraishi; M Razandi; A Terano; T Harada; K J Ivey
Journal:  Dig Dis Sci       Date:  1994-06       Impact factor: 3.199

8.  Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

Authors:  Gang Liu; Ping Men; George Perry; Mark A Smith
Journal:  J Nanoneurosci       Date:  2009-06-01

9.  Inhibition of the hepatocyte uptake of radiolabelled monoclonal antibodies by chelating agents.

Authors:  B R Davidson; P B Boulos; J B Porter
Journal:  Eur J Nucl Med       Date:  1990

10.  Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia.

Authors:  M Hatori; J Sparkman; C C Teixeira; M Grynpas; J Nervina; N Olivieri; I M Shapiro
Journal:  Calcif Tissue Int       Date:  1995-09       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.